Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol

Trials

Volumn 12, Issue , 2011, Pages

  Furukawa, Toshi A ^a   Akechi, Tatsuo ^b   Shimodera, Shinji ^c   Yamada, Mitsuhiko ^d   Miki, Kazuhira ^e   Watanabe, Norio ^b   Inagaki, Masatoshi ^d   Yonemoto, Naohiro ^d  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^e Miki Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIANSERIN; MIRTAZAPINE; PLACEBO; SERTRALINE; VENLAFAXINE; DRUG DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGRANULOCYTOSIS; ANAPHYLAXIS; ARTICLE; COMA; CONSTIPATION; CONVULSION; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; FATIGUE; HEADACHE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; JAUNDICE; LIVER DYSFUNCTION; MAJOR DEPRESSION; NAUSEA; NEUTROPENIA; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SEROTONIN SYNDROME; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW (TOPIC); TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; XEROSTOMIA; ADULT; AGED; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG SUBSTITUTION; FEMALE; JAPAN; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLUSTER ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; JAPAN; MALE; MIANSERIN; MIDDLE AGED; PATIENT SELECTION; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955777857     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-116     Document Type: Article

References (55)

1. WHO The global burden of disease: 2004 update. 2008, WHO., http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289(23):3095-3105. 10.1001/jama.289.23.3095, 12813115.
3. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lepine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martinez-Alonso M, Matschinger H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004, (420):21-27.
4. Kawakami N, Ono Y, Nakane Y, Nakamura Y, Tachimori H, Iwata N, Uda H, Nakane H, Watanabe M, Naganuma Y, Furukawa TA, Hata Y, Kobayashi M, Miyake Y, Takeshima T, Kikkawa T. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: The World Mental Health Japan 2002-2004 Survey. World Mental Health Survey: Global Perspectives on the Epidemiology of Mental Disorders 2008, 474-485. New York: Cambridge University Press, Kessler RC, Ustun TB.
5. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry 2008, 69(11):1675-1685. quiz 1839-1641, 10.4088/JCP.v69n1102, 18945396.
6. Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, Barbui C. Are we going to increase the use of antidepressants up to that of benzodiazepines?. Eur J Clin Pharmacol 2004, 60(9):629-634. 10.1007/s00228-004-0810-8, 15448956.
7. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000, 157(4 Suppl):1-45. American Psychiatric Association.
8. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001, 46(Suppl 1):5S-90S.
9. NICE Depression: the treatment and management of depression in adults (partial update of NICE clinical guideline 23) 2009, London: National Institute for Clinical Excellence, NICE.
10. Motohashi N, . (Ed) Pharmacotherapy Algorithms for Mood Disorders 2003, Tokyo: Jihou, (Ed).
11. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Using Second-Generation Antidepressants to Treat Depressive Disorders: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med 2008, 149(10):725-733.
12. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, Deveaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN. Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians. Ann Intern Med 2008, 149(10):734-750.
13. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758. 10.1016/S0140-6736(09)60046-5, 19185342.
14. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40. 10.1176/appi.ajp.163.1.28, 16390886.
15. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Moller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002, 63(9):826-837. 10.4088/JCP.v63n0913, 12363125.
16. Corruble E, Guelfi JD. Does increasing dose improve efficacy in patients with poor antidepressant response: a review. Acta Psychiatr Scand 2000, 101(5):343-348. 10.1034/j.1600-0447.2000.101005343.x, 10823292.
17. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005, 255(6):387-400. 10.1007/s00406-005-0579-5, 15868067.
18. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006, 189:309-316. 10.1192/bjp.bp.105.018325, 17012653.
19. Furukawa TA, Cipriani A, Barbui C, Geddes JR. Long-term treatment of depression with antidepressants: A systematic narrative review. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie 2007, 52(9):545-552.
20. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006, 67(12):1836-1855. 10.4088/JCP.v67n1203, 17194261.
21. Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001, 103(1):66-72. 10.1034/j.1600-0447.2001.00148.x, 11202131.
22. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007, 68(6):935-940. 10.4088/JCP.v68n0617, 17592920.
23. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996, 53(9):842-848.
24. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166(9):980-991. 10.1176/appi.ajp.2009.09030312, 19687129.
25. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002, 161(2):143-151.
26. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002, 51(2):183-188. 10.1016/S0006-3223(01)01262-8, 11822997.
27. Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol 2010, 24(4):513-20. Epub 2008 Oct 2, 10.1177/0269881108097714, 18832428.
28. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354(12):1231-1242. 10.1056/NEJMoa052963, 16554525.
29. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354(12):1243-1252. 10.1056/NEJMoa052964, 16554526.
30. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 2007, 1-8.
31. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000, 157(4 Suppl):1-45.
32. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009, (2):CD006117.
33. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010, 167(3):281-288. 10.1176/appi.ajp.2009.09020186, 20008946.
34. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003, 361(9358):653-661. 10.1016/S0140-6736(03)12599-8, 12606176.
35. Fujita A, Azuma H, Kitamura T, Takahasi K, Akechi T, Furukawa TA. Adequacy of continuation and maintenance treatments for major depression in Japan. J Psychopharmacol (Oxf) 2008, 22(2):153-156.
36. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009, 339:b2880. 10.1136/bmj.b2880, 2725270, 19671933.
37. Bruce ML, Ten Have TR, Reynolds CF, Katz II, Schulberg HC, Mulsant BH, Brown GK, McAvay GJ, Pearson JL, Alexopoulos GS. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA 2004, 291(9):1081-1091. 10.1001/jama.291.9.1081, 14996777.
38. Wells KB, Sherbourne C, Schoenbaum M, Duan N, Meredith L, Unutzer J, Miranda J, Carney MF, Rubenstein LV. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA 2000, 283(2):212-220. 10.1001/jama.283.2.212, 10634337.
39. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999, 282(18):1737-1744. 10.1001/jama.282.18.1737, 10568646.
40. Pinto-Meza A, Serrano-Blanco A, Penarrubia MT, Blanco E, Haro JM. Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone?. J Gen Intern Med 2005, 20(8):738-742. 10.1111/j.1525-1497.2005.0144.x, 1490180, 16050884.
41. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16(9):606-613. 10.1046/j.1525-1497.2001.016009606.x, 1495268, 11556941.
42. Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care 2004, 42(12):1194-1201. 10.1097/00005650-200412000-00006, 15550799.
43. Muramatsu K, Miyaoka H, Kamijima K, Muramatsu Y, Yoshida M, Otsubo T, Gejyo F. The patient health questionnaire, Japanese version: validity according to the mini-international neuropsychiatric interview-plus. Psychol Rep 2007, 101(3 Pt 1):952-960.
44. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988, 8:77-100.
45. Beck AT, Steer RA, Brown GK. BDI-II: Beck Depression Inventory, Second Edition, Manual 1996, San Antonia: The Psychological Corporation.
46. Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y, Hashimoto N, Watanabe N, Maeda T, Furukawa TA. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Res 2005, 135(3):229-235. 10.1016/j.psychres.2004.03.014, 15996749.
47. Steer RA, Brown GK, Beck AT, Sanderson WC. Mean Beck Depression Inventory-II scores by severity of major depressive episode. Psychol Rep 2001, 88(3 Pt 2):1075-1076.
48. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007, 164(7):1035-1043. 10.1176/appi.ajp.164.7.1035, 17606655.
49. Kroenke K, Bair MJ, Damush TM, Wu J, Hoke S, Sutherland J, Tu W. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 2009, 301(20):2099-2110. 10.1001/jama.2009.723, 2884224, 19470987.
50. Perini S, Titov N, Andrews G. Clinician-assisted Internet-based treatment is effective for depression: randomized controlled trial. Aust N Z J Psychiatry 2009, 43(6):571-578. 10.1080/00048670902873722, 19440890.
51. Dobscha SK, Corson K, Perrin NA, Hanson GC, Leibowitz RQ, Doak MN, Dickinson KC, Sullivan MD, Gerrity MS. Collaborative care for chronic pain in primary care: a cluster randomized trial. JAMA 2009, 301(12):1242-1252. 10.1001/jama.2009.377, 19318652.
52. Cohen J. Statistical Power Analysis in the Behavioral Sciences 1988, Hillsdale, NJ: Erlbaum.
53. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358:252-260. 10.1056/NEJMsa065779, 18199864.
54. Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007, 297(5):468-470.
55. Furukawa TA. From effect size into number needed to treat. Lancet 1999, 353(9165):1680.